long-term use (>2 years) of pioglitazone, an oral hypoglycemic agent for diabetes mellitus, increased the risk of bladder cancer among diabetic patients (hazard ratio, 1.4; 95% confidence interval, 1.0-2.0). 3 Subsequent pooled multipopulation analysis revealed that the cumulative use of pioglitazone was not associated with the incidence of bladder cancer. 4,5 However, the impact of the first result was larger than the beneficial effect of pioglitazone and the use of this drug has decreased worldwide, despite it being reported to reduce the risk of macrovascular events such as nonfatal myocardial infarction, stroke, and all-cause death in patients with type 2 diabetes. 6 Therefore, the mitogenic potency and oncogenicity of drugs should be taken into account, especially in patients who are undergoing longterm drug therapy. Fortunately, there has been no evidence that warfarin itself increases the incidence of renal or bladder cancer. Conversely, an anticancer effect of warfarin can be found in some reports, in which the long-term use of warfarin was associated with a lower incidence of prostate cancer. 7-9 These findings support the first hypothesis.Age is a strong risk factor for the incidence of cancer. Indeed, the odds ratio for genitourinary cancers in patients